
Olaparib Study 19



Olaparib Study 19 PRELIMINARY SCORE **CURATIVE NON-CURATIVE ADJUSTMENTS** Quality of life No QoL benefit Serious and disabling adverse effects Other adjustments Mature data shows no OS advantage and no improved QoL





© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.